It is currently Fri Jul 01, 2016 4:48 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

BHT-3009 Phase II trial begins dosing

Bayhill doses patients with multiple sclerosis in phase II trial, raises $15.8M

Science Letter - May. 12, 2006

Bayhill Therapeutics, Inc., has begun dosing patients with BHT-3009, the company's experimental drug candidate, in a phase II company sponsored trial for multiple sclerosis.

The phase II study is a multicenter, double-blind, placebo-controlled evaluation with an MRI endpoint. In a related development, current investors indicated strong support for Bayhill's antigen-specific tolerance platform by raising an additional $15.8 ...
Read more : BHT-3009 Phase II trial begins dosing | Views : 1425 | Replies : 0


Phase III Trial of Oral Cladribine Starts

Phase III Trial of Oral Cladribine, a Novel Investigational Therapy for Multiple Sclerosis, Begins in the United States
Thursday May 4, 8:17 am ET
Nationwide Recruitment Begins at Sites Across the U.S.

ROCKLAND, Mass. and GENEVA, May 4 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) announced today that recruitment in the U.S. is beginning for the Phase III CLARITY study (CLAdRIbine Tablets in Treating MS OrallY Study) of oral cladribine for the treatment of ...
Read more : Phase III Trial of Oral Cladribine Starts | Views : 2320 | Replies : 6


MBP8298

Not big news, but it's another hurdle jumped...



BioMS Medical's pivotal multiple sclerosis trial receives fourth positive review from Data Safety Monitoring Board

May 3 - CNW - BioMS Medical today announced that following the fourth meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.

"The recommendation by the independent DSMB ...
Read more : MBP8298 | Views : 3027 | Replies : 5


Allon Therapeutics

They say they plan to initiate phase II trials in 2006, and that there will be multiple trials, so I hope they include MS...



Allon Therapeutics Presents CSF and Bioavailability Data at IBC's TIDES 2006

CCNMatthews - May 2, 2006 - Allon Therapeutics Inc. has presented a case study during IBC's "TIDES 2006: Oligonucleotide and Peptide Technology and Product Development" in Carlsbad, California.

This pre-clinical study confirmed that Allon's drug candidates penetrate the blood brain ...
Read more : Allon Therapeutics | Views : 1410 | Replies : 0


Blockbusters

They are talking about "blockbusters" for MS over the next 10 years. I think that means a drug with over US$ 1 billion in annual revenues. They may be right that there aren't any on the horizon for MS, but I don't think it's correct that there won't be any new drugs in the next 10 years which are far more effective than anything we have today, including Tysabri.



FDA's Likely Approval to Relaunch Tysabri, ...
Read more : Blockbusters | Views : 1929 | Replies : 5


New treatments

Came across this list of treatments - probably a bit out of date but a good summary.

Ian

http://msrrtc.washington.edu/resources/NewMSDrugs.asp
Read more : New treatments | Views : 1897 | Replies : 2


CD83

Well, at least there are a lot of early-stage treatments getting mentioned in the press right now -- it's better than nothing...



Argos Therapeutics, Beckman Coulter Sign License Agreement; CD83 Licensure to Advance Work on Autoimmune Disorders, Transplant Rejection Therapy

BUSINESS WIRE - April 26, 2006 - Argos Therapeutics, a company pioneering new approaches in immunotherapy, announced today that it has entered into an agreement with California-based Beckman Coulter granting Argos exclusive therapeutic use rights ...
Read more : CD83 | Views : 1339 | Replies : 0


15d-PGJ(2)

Here's another one I just stumbled across that I think qualifies for pre-clinical...



Hormone regulation of microglial cell activation: relevance to multiple sclerosis.

Brain Res Brain Res Rev. 2005 Apr;48(2):322-7. Epub 2005 Jan 19.
Drew PD, Storer PD, Xu J, Chavis JA.
Department of Neurobiology and Developmental Sciences-Slot 510, University of Arkansas for Medical Sciences, Shorey Building, Little Rock, 72205, USA. drewpauld@uams.edu

Peroxisome proliferator-activated receptors (PPARs) are members of the ...
Read more : 15d-PGJ(2) | Views : 2146 | Replies : 4


Methylthioadenosine (whatever that means)

Sounds like this research is still in the early stages, but they mention that MTA could be of benefit in MS, so I think it will go in the "pre-clinical" section of the pipeline.



Protective action of a molecule in inflammatory processes discovered

Henar Hevia Pérez, researcher in the area of Genic Therapy and Hepatology at the Applied Medicine Research Centre (CIMA)of the University of Navarra, has discovered the protective role of the methylthioadenosine (MTA) ...
Read more : Methylthioadenosine (whatever that means) | Views : 1384 | Replies : 0


FTY720

Novartis published first quarter results today. The following info was provided on FTY720:

FTY720 (fingolimod), an oral once-daily treatment for relapsing forms of multiple sclerosis (MS), is currently in Phase III development. Discussions are continuing with the FDA on starting a Phase III study in the US. Data from an extension of a Phase II trial to 18 months presented in April confirmed the substantial efficacy of FTY720 in significantly reducing the relapse rate and ...
Read more : FTY720 | Views : 1884 | Replies : 1


 

Login  •  Register


Statistics

Total posts 232998 • Total topics 24955 • Total members 16092


Contact us | Terms of Service